GHENT, Belgium—Europital announced an expansion in September, launching new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing services of medical affairs and medical writing. The company already had regional offices in Belgium, Hungary and the United Kingdom—and customers based in both Europe and the United States—but this expanded clinical research offering will see Europital support clients as a full-service contract research organization (CRO) in over 40 countries from their Investigational New Drug application needs through to commercial launch.
Europital expands into a full-service CRO
New capabilities include project management, clinical monitoring and pharmacovigilance| 2 min read
To continue reading this article, subscribe for FREE to
Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.
About the Author
- This person does not yet have a bio.
Related Topics
Published In
GHENT, Belgium—Europital announced an expansion in September, launching new capabilities across project management, clinical monitoring, biostatistics, pharmacovigilance, regulatory affairs and data management, in addition to its existing services of medical affairs and medical writing. The company already had regional offices in Belgium, Hungary and the United Kingdom—and customers based in both Europe and the United States—but this expanded clinical research offering will see Europital support clients as a full-service contract research organization (CRO) in over 40 countries from their Investigational New Drug application needs through to commercial launch.
In addition to its regional offices in Europe, Europital has built a global network of trusted partners over the last 10 years, with local operational expertise and preferential supply trial site agreements in the United States, Canada, Russia, India, the Middle East, North Africa and Australia. The company’s goal is to continue building partnerships to become the leading science-based CRO for small to mid-sized pharma and biotech companies.
“We are delighted to announce that we can now provide a full, 360-degree CRO service to innovators in the pharmaceutical, biotechnology and medical devices sectors. Europital has seen a robust expansion in the last few years, and we have been steadily preparing to launch full service capabilities,” commented Dr. Mohamed El Malt, chief medical officer of Europital. “It’s no secret there is a large gap in the CRO industry for these small innovators. What they need is a science-driven CRO that will support them closely with an experienced senior team but combined with a global trial network.”
Europital is now providing a full range of services for clinical research and other drug and medical device development phases, and collaborating with sponsors in the pharmaceutical, biotechnology and medical device industries, as well as governmental and scientific institutes. Europital’s multifunctional and operational capabilities are expected to mainly benefit innovators developing therapies for oncology, infectious diseases, inflammatory and autoimmune diseases, particularly those that require a full range of CRO services for complex molecules and trial designs that necessitate senior medical and scientific oversight.
The difference in the service Europital offers is the presence of the company’s senior team from contract to commercialization. In other words, Europital says, sponsors will retain the same experienced team throughout the lifecycle of their development plan. Europital is primarily staffed by physicians and has significant experience in the clinical development of treatments for complex oncology, infectious diseases, inflammatory and autoimmune disease indications.
The decision to launch as a full-service CRO comes after years of requests from clients to work on additional aspects of their clinical trials. Unfortunately, these were services Europital could not yet provide in-house. This launch now allows the company to support clients throughout the entire trial process.
Concluded El Malt: “Although we have evolved from being a niche provider of medical management services to be able to offer the full range of services of a contract research organization, we maintain the philosophy, ethic and driving force of Europital to put not profit or expediency—but [rather] the scientific validity of study results and the safety of the patients—first. These values have enabled us to have satisfied sponsors and a 100-percent repeat business rate.”
